HSPA5 and pancreatic neoplasm: Anti-CLPTM1L antibodies have been shown to inhibit anchorage-independent growth, GRP78-mediated chemoresistance, and AKT phosphorylation in pancreatic tumors, suggesting a unique and potentially targetable mechanism of cytoprotection and resistance to chemotherapy [42].